Literature DB >> 1387026

Pharmacological characterization of 5-hydroxytryptamine-induced excitation of afferent cervical vagus nerve in anaesthetized rats.

M Yoshioka1, T Ikeda, M Abe, H Togashi, M Minami, H Saito.   

Abstract

1. An excitatory response to 5-hydroxytryptamine (5-HT) was measured from the afferent vagus nerve of anaesthetized rats. Measurements were determined by an extracellular recording from the whole nerve. 2. Intravenous bolus injection of 5-HT (1.56-100 micrograms kg-1) evoked a dose-dependent excitation of afferent vagus nerve activity. This response was blocked not only by a selective 5-HT3 receptor antagonist, GR38032F (10 and 100 micrograms kg-1), but also by a 5-HT2 receptor antagonist, ketanserin (10 and 100 micrograms kg-1). 3. Both a 5-HT3 receptor agonist, 2-methyl-5-HT (3.12-100 micrograms kg-1), and a 5-HT2 receptor agonist, alpha-methyl-5-HT (3.12-50 micrograms kg-1), produced a dose-dependent excitation of afferent vagus nerve activity. These excitatory effects were antagonized by GR38032F (10 micrograms kg-1) and ketanserin (10 micrograms kg-1), respectively. 4. A 5-HT1 like receptor agonist, 5-carboxamidotryptamine (50 micrograms kg-1), and a putative 5-HT4 receptor agonist, 5-methoxytryptamine (100 micrograms kg-1), failed to produce excitatory effects on the afferent vagus nerve. 5. These results suggest that the 5-HT-induced excitatory response of the afferent vagus nerve might be mediated not only via 5-HT3 receptors but also via 5-HT2 receptors in anaesthetized rats. It is unlikely, however, that either 5-HT1-like or putative 5-HT4 receptors are involved in the excitatory response of the afferent vagus nerve to 5-HT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387026      PMCID: PMC1907555          DOI: 10.1111/j.1476-5381.1992.tb14372.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  [3H]ICS 205-930 labels 5-HT3 recognition sites in membranes of cat and rabbit vagus nerve and superior cervical ganglion.

Authors:  D Hoyer; C Waeber; A Karpf; H Neijt; J M Palacios
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

2.  Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors.

Authors:  A Butler; J M Hill; S J Ireland; C C Jordan; M B Tyers
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

3.  Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle.

Authors:  M L Cohen; K W Schenck; W Colbert; L Wittenauer
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

4.  Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.

Authors:  P B Bradley; G Engel; W Feniuk; J R Fozard; P P Humphrey; D N Middlemiss; E J Mylecharane; B P Richardson; P R Saxena
Journal:  Neuropharmacology       Date:  1986-06       Impact factor: 5.250

5.  Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin.

Authors:  R B McCall; M R Schuette
Journal:  J Pharmacol Exp Ther       Date:  1984-03       Impact factor: 4.030

6.  Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

Authors:  B P Richardson; G Engel; P Donatsch; P A Stadler
Journal:  Nature       Date:  1985 Jul 11-17       Impact factor: 49.962

7.  The depolarizing action of 5-HT on mammalian non-myelinated nerve fibres.

Authors:  F Riccioppo Neto
Journal:  Eur J Pharmacol       Date:  1978-06-15       Impact factor: 4.432

8.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

9.  Neuronal 5-HT receptors in the periphery.

Authors:  J R Fozard
Journal:  Neuropharmacology       Date:  1984-12       Impact factor: 5.250

10.  The depolarizing action of 5-hydroxytryptamine on rabbit vagal afferent and sympathetic neurones in vitro and its selective blockade by ICS 205-930.

Authors:  A Round; D I Wallis
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

View more
  5 in total

1.  Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat.

Authors:  J X Zhu; X Y Zhu; C Owyang; Y Li
Journal:  J Physiol       Date:  2001-02-01       Impact factor: 5.182

2.  Impact of the vagal feedback on cardiorespiratory coupling in anesthetized rats.

Authors:  Irina Topchiy; Miodrag Radulovacki; Jonathan Waxman; David W Carley
Journal:  Respir Physiol Neurobiol       Date:  2010-12-31       Impact factor: 1.931

3.  Effect of Systemic Application of 5-Hydroxytryptamine on Hypoglossal Nerve Discharge in Anesthetized Rats.

Authors:  Xueping Tu; Jinjing Zuo; Ke Hu; Jing Kang; Yongtian Mei; Nian Wang
Journal:  J Mol Neurosci       Date:  2015-06-16       Impact factor: 3.444

4.  Cardiorespiratory effects of intertrigeminal area stimulation in vagotomized rats.

Authors:  Irina Topchiy; Miodrag Radulovacki; Jonathan Waxman; David W Carley
Journal:  Brain Res       Date:  2008-11-11       Impact factor: 3.252

5.  Local antagonism of intertrigeminal region metabotropic glutamate receptors exacerbates apneic responses to intravenous serotonin.

Authors:  Milan Stoiljkovic; Miodrag Radulovacki; David W Carley
Journal:  Respir Physiol Neurobiol       Date:  2008-11-05       Impact factor: 1.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.